Cardiff Oncology (NASDAQ:CRDF) – Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022 - Press Release

Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FO

Related Keywords

Arizona ,United States ,Kansas ,Paris ,France General ,France ,Giessen ,Alsace ,Texas ,Heinz Josef Lenz ,Acta Oncologica ,Scott Kopetz ,Amy Jobe ,Joyce Allaire ,James Levine ,Division Of Cancer Medicine ,Cardiff Oncology Inc ,Inova Schar Cancer Institute ,University Of Texas Md Anderson Cancer Center ,Cancer Center ,Department Of Gastrointestinal Medical Oncology ,Exchange Commission ,Lifesci Communications ,Kansas University Medical Center ,Norris Comprehensive Cancer Center ,European Society For Medical Oncology ,Access Program ,Expanded Access Program ,Cardiff Oncology ,European Society ,Medical Oncology ,Paris Expo Porte De Versailles ,Yearly Decreases ,Allele Frequency ,Predict Clinical Benefit ,Metastatic Colorectal Carcinoma ,Comprehensive Cancer Center ,Onvansertib Overcomes Irinotecan Resistance ,Metastatic Colorectal Cancer ,Gastrointestinal Medical Oncology ,Cancer Medicine ,Poster Sessions ,Corporate Update Conference Call ,Second Line Treatment ,Line Treatment ,Mayo Clinic ,Inova Schar Cancer ,Lancet Oncol ,Correspondence Lancet Oncol June ,Private Securities Litigation Reform Act ,Oncology Contact ,